Last Updated : May 2, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name | Therapeutic Area Sort descending | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Reblozyl | luspatercept | Myelodysplastic syndromes-associated anemia | Reimburse with clinical criteria and/or conditions | Complete | ||
| Inrebic | fedratinib | Myelofibrosis | Reimburse with clinical criteria and/or conditions | Complete | ||
| Jakavi | Ruxolitinib | Myelofibrosis | Reimburse with clinical criteria and/or conditions | Complete | ||
| Lucentis | Ranibizumab | Myopic choroidal neovascularisation | List with criteria/condition | Complete | ||
| Wakix | pitolisant hydrochloride | Narcolepsy | Do not reimburse | Complete | ||
| Xyrem | Sodium oxybate | Narcolepsy | Withdrawn | |||
| Xyrem | Sodium oxybate | Narcolepsy | Do not list | Complete | ||
| Akynzeo | netupitant / palonosetron | Nausea and vomiting (chemotherapy induced) prevention | Reimburse with clinical criteria and/or conditions | Complete | ||
| Emend | Aprepitant | Nausea and Vomiting, Chemotherapy induced | List with clinical criteria and/or conditions | Complete | ||
| Perjeta or Perjeta-Herceptin Combo Pack | Pertuzumab | Neoadjuvant Breast Cancer | Do not reimburse | Complete |
Last Updated : May 2, 2024